ArticleBMC cancer2026
The influence of the administration sequence of neoadjuvant immunotherapy combined with chemotherapy on the postoperative pathological response of stage IIA-IIIB non-small cell lung cancer.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to evaluate whether the within-cycle sequence of neoadjuvant immunochemotherapy influences postoperative pathological response in patients with stage IIA–IIIB non-small cell lung cancer (NSCLC).
methodsWe retrospectively enrolled 192 patients with stage IIA–IIIB NSCLC who received neoadjuvant immunochemotherapy. Patients were divided into Group A (chemotherapy on day 1 followed by immunotherapy on day 2, n = 122) and Group B (immunotherapy on day 1 followed by chemotherapy on day 2, n = 70). Propensity score matching (1:1, caliper = 0.2) created 62 matched pairs. The primary endpoint was postoperative pathological response including pathological complete response and major pathological response. Conditional logistic regression was used, and E‑values were calculated for sensitivity analysis. Secondary endpoints included objective response rate (ORR), safety, and perioperative outcomes.
resultsAfter matching, baseline characteristics were well balanced. The pathological response rate was higher in Group A than in Group B (50.00% vs. 30.64%; univariate OR = 2.33, 95%CI 1.07–5.09, P = 0.033; multivariable OR = 4.78, 95%CI 1.24–18.46, P = 0.023). E‑value analysis suggested that the observed association may be relatively robust to unmeasured confounding (univariate E = 4.09, multivariable E = 9.03). ORR was also higher in Group A (72.58% vs. 51.65%; OR = 2.62, 95%CI 1.16–5.93, P = 0.020). Grade ≥ 3 treatment‑related adverse events were similar between groups (35.48% vs. 29.03%, P = 0.494). Operative time was longer in Group A (180 vs. 165 min, P = 0.037), but no differences were observed in R0 resection rate, postoperative complications, or other surgical outcomes.
conclusionIn patients with stage IIA–IIIB NSCLC, the within-cycle administration sequence of chemotherapy followed by immunotherapy was associated with a higher postoperative pathological response rate. This dosing sequence may have clinical optimization value, but further validation through prospective studies is still needed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.